Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
pharmaceuticals: Archive
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
KOPositive Net Change LLYNegative Net Change ETNNegative Net Change
consumer-staples pharmaceuticals utilities
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
NVOPositive Net Change LLYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change
pharmaceuticals
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
by Zacks Equity Research
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
REGNPositive Net Change PFEPositive Net Change NVOPositive Net Change AMGNNegative Net Change MRNAPositive Net Change
biotechs earnings gene-therapy immuno-therapy medical messenger-rna pharmaceuticals vaccines
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
AMZNNegative Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXPositive Net Change MCDNegative Net Change SMCINegative Net Change
consumer-staples multi-sector-conglomerates pharmaceuticals restaurants
Pre-Markets Sell on Last Trading Day of April
by Mark Vickery
Today we close out a month that's likely to be the first negative one since October of last year.
AMZNNegative Net Change KOPositive Net Change LLYNegative Net Change MMMPositive Net Change SBUXPositive Net Change MCDNegative Net Change SMCINegative Net Change
consumer-discretionary earnings industrial-products pharmaceuticals
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Vertex's (VRTX) revenues in the first quarter of 2024 are likely to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
ALNYNegative Net Change VRTXPositive Net Change CRSPPositive Net Change ALPNPositive Net Change
biotechnology biotechs crispr earnings gene-editing gene-therapy medical pharmaceuticals
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its late-stage pipeline candidates when it reports first-quarter earnings.
MRKNegative Net Change MRNAPositive Net Change SRPTNegative Net Change ARGXNegative Net Change
biotechs earnings medical messenger-rna pharmaceuticals vaccines
Collegium (COLL) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Collegium's (COLL) top line is likely to have been fueled by growth in the sales of pain drugs, Belbuca and Xtampza ER, in the first quarter of 2024.
UTHRPositive Net Change EXELNegative Net Change SRPTNegative Net Change COLLPositive Net Change
biotechs earnings pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
ALNYNegative Net Change SRPTNegative Net Change ARGXNegative Net Change OCGNPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) first-quarter earnings and sales beat estimates. Management hikes the EPS guidance on the back of encouraging Skyrizi product sales.
RHHBYNegative Net Change JNJPositive Net Change ABBVPositive Net Change GMABPositive Net Change
biotechs earnings medical pharmaceuticals
Pharma Stock Roundup: MRK, SNY, AZN, NVS' Q1 Results, Pipeline & Regulatory Updates
by Kinjel Shah
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
SNYPositive Net Change AZNPositive Net Change NVSPositive Net Change JNJPositive Net Change MRKNegative Net Change
pharmaceuticals
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
by Zacks Equity Research
Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
BIIBPositive Net Change LGNDNegative Net Change ANIPNegative Net Change SAGEPositive Net Change
biotechs medical pharmaceuticals
PCE/Core PCE Numbers Came In Line With Expectations
by Zacks Equity Research
PCE/Core PCE Numbers Came In Line With Expectations
XOMNegative Net Change ABBVPositive Net Change
oil-energy pharmaceuticals
PCE In-Line to Warmer, Pre-Market Calms; ABBV Beats, XOM Misses
by Mark Vickery
Pre-market futures are up across the board: +106 points on the Dow, +45 points on the S&P 500 and +195 on the Nasdaq immediately following this important data's release.
XOMNegative Net Change ABBVPositive Net Change
consumer-discretionary consumer-staples energy inflation pharmaceuticals
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.
GILDPositive Net Change ANIPNegative Net Change ADMANegative Net Change XLONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKNegative Net Change SRPTNegative Net Change FUSNNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
5 Stocks in Focus on Their Recent Dividend Hike
by Nalak Das
Five stocks to focus with recent dividend hike are: JNJ, TRV, SON, KBH, SPFI.
JNJPositive Net Change TRVNegative Net Change SONPositive Net Change KBHNegative Net Change SPFINegative Net Change
business-services construction finance industrial-products pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
by Zacks Equity Research
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
BIIBPositive Net Change BMYPositive Net Change VRTXPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up
by Zacks Equity Research
AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.
SNYPositive Net Change AZNPositive Net Change MRKNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals vaccines
Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
by Zacks Equity Research
Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.
AZNPositive Net Change MRKNegative Net Change ANIPNegative Net Change ADMANegative Net Change
pharmaceuticals
Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2024 loss is narrower than estimated. Sales surpass the consensus mark on the back of Eliquis, Reblozyl and Opdualag's encouraging performance. However, Opdivo sales disappoint.
BMYPositive Net Change PFEPositive Net Change ANIPNegative Net Change ADMANegative Net Change
biotechnology biotechs earnings pharmaceuticals
Sanofi (SNY) Q1 Earnings In Line, Sales Miss Estimates, Stock Up
by Zacks Equity Research
Sanofi (SNY) posts first-quarter 2024 results and maintains the earnings growth guidance for the year.
REGNPositive Net Change SNYPositive Net Change AZNPositive Net Change ADMANegative Net Change
pharmaceuticals
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
ALNYNegative Net Change SRPTNegative Net Change ZTSNegative Net Change BLUENegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change ABBVPositive Net Change
pharmaceuticals
New Strong Buy Stocks for April 25th
by Zacks Equity Research
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
EROPositive Net Change RMNINegative Net Change TAKNegative Net Change PEPGNegative Net Change TXOPositive Net Change
oil-energy pharmaceuticals